Navrogen
Oncology Therapeutics · Health Care
Overview
Leading the Way in Humoral Immuno-Oncology. At Navrogen, our team of experts is striving to provide innovative solutions to overcome immunosuppressive mechanisms at play in the Humoral Immuno-Oncology space.
Funding and backers
Total raised
$12.8M
3 rounds on record
Latest round
$542k
Convertible Note · Jun 2024 · 2 yr ago
Team
11-50
employees, estimated range
The money's age
Long since its last round
29 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 5, 2024
Raised a round Convertible Note $542k · SEC Form D
Jul 29, 2021
Raised a round Venture round $9.1M · SEC Form D
Oct 10, 2018
Raised a round Convertible Note $3.2M · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Convertible Note | Jun 2024 | $542k | — | SEC Form D |
| Venture round | Jul 2021 | $9.1M | — | SEC Form D |
| Convertible Note | Oct 2018 | $3.2M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Navrogen Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Nicholas NicolaidesExecutive Officer, DirectorSEC Form D
Luigi GrassoExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
backs Cytosolix
Similar startupsby what they do, their industry and backers
We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
Imcheck Therapeutics : Opening new spaces in Immuno-Oncology.
Lever Bio aims to translate groundbreaking discoveries in immuno-oncology into next-generation cancer immunotherapies.
At Oxford BioTherapeutics, we are dedicated to pioneering the next generation of oncology treatments through targeted therapies, including…
Our Tumor Activated Permeability (TAP) Platform produces weakly-acidic derivatives of known oncology drugs that already work. It preserves…
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and…
People
Nicholas Nicolaides
Executive Officer, Director
Luigi Grasso
Executive Officer, Director
Leon Moulder Jr
Director
Allan Bedwick
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data